Topics

Mitochon Pharmaceuticals, Inc. Company Profile

00:04 EST 23rd January 2020 | BioPortfolio

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival – similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Additional Information: www.mitochonpharma.com


News Articles [541 Associated News Articles listed on BioPortfolio]

FDA approves nine generic versions of Pfizer's Lyrica

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the commercial green light to not one, but nine different analogue therapies. The...

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Leadership Update

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec.....

GW Pharmaceuticals: Überzeugende Quartalszahlen

Kulmbach (www.aktiencheck.de) - GW Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die GW Pharmaceuticals....

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Sobi to buy Dova Pharmaceuticals in $915m deal

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post So...

Drugs and Medications [0 Results]

None

PubMed Articles [121 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status.

Pharmaceuticals are organic compounds used in medicines for alleviation of pain. Since 2017, there has been a steady increase on the availability of information on contamination of water resources cau...

Prioritization of pharmaceuticals in water environment in China based on environmental criteria and risk analysis of top-priority pharmaceuticals.

Numerous studies have shown that a wide range of pharmaceuticals are present in the environment and many of their adverse biological effects on the aquatic ecosystem and human health are unknown. Due ...

Biological-activity-based prioritization of pharmaceuticals in wastewater for environmental monitoring: G protein-coupled receptor inhibitors.

Pharmaceuticals raise concerns for aquatic species owing to their biological activities. It is estimated that nearly 40% of marketed pharmaceuticals target G protein-coupled receptors (GPCRs). Using a...

Clinical Trials [251 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1410 Associated Companies listed on BioPortfolio]

LDM Group and Mitochon Systems

Mitochon Systems Inc. was founded in 2006 by Andre Vovan, MD, MBA, FCCM, who is the Director of a Critical Care Department at a large California hospital. He created a system base...

Mitochon Pharmaceuticals, Inc.

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegenerati...

Mitochon Systems

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

More Information about "Mitochon Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Mitochon Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Mitochon Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Mitochon Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mitochon Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Mitochon Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record